N/A N=20 HAART 200 Aortic Valve Annuloplasty Trial
Aortic Insufficiency
Primary: Primary Safety Outcome Measure: Survival Defined as Survival Free From All Cause Death at 6 Months Postprocedure. — 100 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=31 Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo
Healthy
Primary: Change in Body Weight — 3.2; 0.8; 0.4 kg
Phase 4 N=567 Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Participants Who Made at Least One Critical Error After Reading the Patient Information Leaflet — 2; 4; 1; 4 Percentage of participants — p=<0.001
Phase 4 N=41 EMD and/or Bone Substitute for the Treatment of Class II Furcations
Periodontal Disease
Primary: Relative Horizontal Clinical Attachment Level (RHCAL) at 12 Months — 2.31; 3.00; 2.57 mm
N/A N=11 Physical and Social Benefits of Multi-Player Interactive Computer Play Games in Youth With Cerebral Palsy
Cerebral Palsy
Primary: Change in the 7.5 Meter Shuttle Run Test for Gross Motor Function Classification Scale (GMFCS) Level III (SRT-III) — 8.3; 8.6; 1.1; 0.7 units on a scale
Phase 4 N=20 Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne
Acne Vulgaris
Primary: Adherence — 46.5 percentage of doses actually applied
Phase 2 N=42 Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Follicular Lymphoma · Marginal Zone Lymphoma · Small Lymphocytic Lymphoma
Primary: Efficacy: Complete Response Rate (CRR) — 9.5 percentage of patients
Phase 2 N=26 A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC
Recurrent Non-Small Cell Lung Carcinoma · Stage IB Non-Small Cell Lung Carcinoma · Stage IIA Non-Small Cell Lung Carcinoma
Primary: Change in 18F-Fluorothymidine (FLT) Uptake — -0.4 SULmax
Phase 4 N=25 Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis
Atopic Dermatitis
Primary: Adherence to Locoid — .55; .60; .50 percentage of days
Phase 1 N=21 Brain Dynamics of Oxytocin
Brain Dynamics in Healthy Adults
Primary: Number of Benevolent Rounds — 6.8; 6.8 number of rounds
Phase 3 N=798 Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Seroconverted (SCR) Subjects for Anti-Human Papillomavirus Type 16 (Anti-HPV-16) and Anti-Human Papillomavirus Type 18 (Anti-HPV-18) — 118; 127; 126; 371…
N/A N=73 GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence
Alcoholism
Primary: Visual Analog Scales of Similarity to Alcohol - Baseline — 0; 0; 0; 0 units on a scale
Phase 1 N=5 PET Imaging and Bariatric Surgery
Obesity, Morbid
Primary: Regional DRD2/3 Binding Percent Changes After Bariatric Surgery — -10.14; -9.39; -8.11; -8.76 percentage of binding potential change
Phase 3 N=203 Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers
Hereditary Periodic Fevers
Primary: Percentage of Participants With Resolution of Initial Flare and Absence of New Flares up to the End of the Randomized Treatment Epoch (16 Weeks) — 61.29; 6.25; 35.14…
Phase 4 N=50 Pain Control With Total Knee Replacement
Postoperative Pain
Primary: Patient Pain Scores — 33.6; 40.0; 34.9; 46.3 units on a scale- VAS